Gilead Sciences
Foster City, California, United States · Biopharma, Biotechnology, Health Care
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, cancer and inflammation. Gilead operates in more than 35 countr
Key facts
- Headquarters
- Foster City, California, United States
- Employees
- 17,000
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (GILD)
- Website
- www.gilead.com
- Company page
Recent activity at Gilead Sciences
- : Gilead and PAHO Forge Partnership to Enhance Access to Lenacapavir for HIV Prevention in Latin America and the Caribbean.
- : Gilead Sciences Expands Collaboration with WHO to Combat Visceral Leishmaniasis.
- : SEC 8-K (1.01): On May 20, 2026, Gilead Sciences, Inc. entered into an Eleventh Supplemental Indenture with Computershare Trust Company, as trustee, to issue $3 billion in Senior Notes, consisting of $500 million due 2028, $1 billion due 2029, $1 billion due 2031, and $500 million due 2034. The Notes bear interest rates ranging from 4.250% to 4.900%, with semi-annual payments. The net proceeds are designated for general corporate purposes, including potential acquisitions and investments. The agreement includes restrictions on incurring additional secured debt, and conditions for repurchasing the Notes in specific change of control scenarios.
- : Gilead Sciences to acquire MacroGenics for $1.7B
- : SEC 8-K (8.01): On April 28, 2026, Gilead Sciences, Inc. completed the acquisition of Arcellx, Inc., a Delaware corporation. This event marks a significant strategic move for Gilead, expanding its portfolio in the biopharmaceuticals sector. The financial details of the acquisition were not specified in the filing, but the completion date aligns with the regulatory reporting requirements. This acquisition is expected to enhance Gilead's competitive positioning and provide access to innovative therapies in the market.
- : SEC 8-K (8.01): Gilead completed the acquisition of the Company on April 28, 2026, following the execution of a Merger Agreement with Parent and Ravens Sub, Inc. Under the terms of the agreement, Gilead purchased all issued and outstanding shares of common stock at a price of $115.00 per share, along with a contingent value right (CVR) which entitles holders to an additional payment of $5.00 per CVR, conditioned on sales exceeding $6.0 billion by December 31, 2029. The tender offer commenced on March 6, 2026, and expired on April 27, 2026, with approximately 77.2% of outstanding shares tendered, satisfying the necessary conditions for the acquisition to proceed. This strategic acquisition emphasizes Gilead's intent to enhance its portfolio in the biotechnology sector.
- : Gilead to acquire Ouro Medicines for $2 billion
- : Gilead Sciences to Acquire Arcellx, Inc. in Merger Agreement
- : SEC 8-K (1.01): On February 22, 2026, Gilead Sciences, Inc. entered into a Merger Agreement with Arcellx, Inc. and Ravens Sub, Inc. The agreement outlines Gilead's intention to acquire all outstanding shares of Arcellx at a price of $115.00 per share in cash, along with contingent value rights for a potential additional $5.00 upon achieving specified milestones. The tender offer will remain open for a minimum of 20 business days, contingent upon the tendering of sufficient shares and other customary conditions, including regulatory approvals. This acquisition aims to enhance Gilead's portfolio in the biotechnology sector, potentially allowing for strategic synergies between the two companies.
- : SEC 8-K (1.01): On February 22, 2026, Gilead Sciences, Inc. entered into an Agreement and Plan of Merger with Arcellx, Inc. and its wholly owned subsidiary, Ravens Sub, Inc. This agreement outlines Gilead's intention to commence a tender offer to acquire all issued and outstanding shares of Arcellx's common stock, excluding certain shares held by the company. As part of this strategic move, the transaction is expected to enhance Gilead's portfolio and market position in the biotechnology sector, illustrating a significant expansion of Gilead’s operational capabilities in the healthcare market. The financial details regarding the offer price have not been disclosed in the filing.
Gilead Sciences funding history
| Date | Round | Amount |
|---|---|---|
| Jun 2022 | Series F | $42.0M |
Leadership
- Daniel O'Day, Chairman and Chief Executive Officer
- Michael Levy, Senior VP Medical Affairs · Regulatory Affairs · Patient Safety · R&D Quality
- Keeley Wettan, General Counsel
- Dietmar Berger, Chief Medical Officer
Verified email and direct lines for Gilead Sciences’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Gilead Sciences files 6 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Nov 2026.
Gilead Sciences in the news
- DZ Bank Adjusts Price Target on Gilead Sciences to $191 From $167 - Yahoo Finance (Nov 04, 2026)
- Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow - BioSpace (Nov 03, 2026)
- Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026 - Business Wire (Nov 04, 2026)
- Gilead Sciences Stock: Analyst Estimates & Ratings - Yahoo Finance (Nov 03, 2026)
- Why Gilead Sciences (GILD) Is Back In The Spotlight - Simply Wall St (Nov 03, 2026)
- Did Earnings Beat Just Shift Gilead Sciences (GILD) Investment Narrative? - Simply Wall St (Nov 01, 2026)
- Gilead Sciences, Inc. Q3 2026 Earnings Call Summary - Yahoo Finance (Oct 30, 2026)
- Access Strategy for Long-Acting PrEP - Gilead Sciences (Feb 10, 2025)
Companies similar to Gilead Sciences
- BioNTech · Biopharma, Biotechnology, Health Care, Therapeutics
- Jazz Pharmaceuticals plc · Biopharma, Biotechnology, Health Care, Therapeutics
- Alnylam Pharmaceuticals · Biopharma, Biotechnology, Health Care, Therapeutics
- Foresee Pharmaceuticals · Biopharma, Biotechnology, Health Care, Therapeutics
- Daiichi Sankyo · Biopharma, Biotechnology, Health Care, Therapeutics
About Gilead Sciences: questions and answers
What does Gilead Sciences do?
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, cancer and inflammation. Gilead operates in more than 35 countr
Where is Gilead Sciences headquartered?
Gilead Sciences is headquartered in Foster City, California, United States.
How many employees does Gilead Sciences have?
Gilead Sciences has about 17,000 employees.
Has Gilead Sciences raised funding?
Yes. Fundz has recorded 1 funding event for Gilead Sciences. The most recent, Series F of $42.0M, was in Jun 2022.
Who leads Gilead Sciences?
Daniel O'Day is a Chairman and Chief Executive Officer at Gilead Sciences.
What is the latest news on Gilead Sciences?
On Sep 16, 2026, Gilead and PAHO Forge Partnership to Enhance Access to Lenacapavir for HIV Prevention in Latin America and the Caribbean.
Is Gilead Sciences a public company?
Yes. Gilead Sciences is publicly traded under the ticker GILD.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy